| 艾曲泊帕治疗原发免疫性血小板减少症患者的回顾性研究 |
| |
| 引用本文： | 金珍琳,金婷,庄强. 艾曲泊帕治疗原发免疫性血小板减少症患者的回顾性研究[J]. 中国现代医生, 2024, 62(11): 69-72 |
| |
| 作者姓名： | 金珍琳 金婷 庄强 |
| |
| 作者单位： | 温州医科大学附属第一医院血液内科,浙江温州 325000 |
| |
| 基金项目： | 浙江省温州市基础性医疗卫生科技项目（Y2020548） |
| |
| 摘 要： | 目的 探究艾曲泊帕治疗原发免疫性血小板减少症(primary immune thrombocytopenia,ITP)患者的回顾性研究。方法 回顾性分析2018年10月至2022年2月于笔者医院接受治疗的90例ITP患者的病历资料,根据不同治疗方式,分为地塞米松组和艾曲泊帕组,地塞米松组采用地塞米松治疗,艾曲泊帕组在地塞米松组基础上联合艾曲泊帕治疗(均n=45)。比较免疫功能、治疗效果及不良反应。结果 治疗后4周,白细胞介素[(interleukin)-2,IL-2]、干扰素-γ(interferon-gamma,INF-γ)水平比较,艾曲泊帕组及地塞米松组均较治疗前降低,且艾曲泊帕组低于地塞米松组,IL-4水平比较,艾曲泊帕组及地塞米松组较治疗前提高,且艾曲泊帕组高于地塞米松组(P<0.05)。治疗后4周,艾曲泊帕组及地塞米松组血小板(platelet,PLT)计数≥30×109/L比例分别为68.89%、40.00%,PLT≥50×109/L比例分别为55.55%、20.00%,艾曲泊帕组各比例均高于地塞米松组(P<0.05)...
|
| 关 键 词： | 艾曲泊帕 原发免疫性血小板减少症 免疫功能 不良反应 |
Retrospective study on the treatment of patients with primary immune thrombocytopenia with atrepopa |
| |
| Abstract: | Objective To investigate the retrospective study of the treatment of primary immune thrombocytopenia (ITP) with Aitracopol. Methods Medical records of 90 patients with ITP who received treatment in our hospital from October 2018 to February 2022 were retrospectively analyzed and grouped according to different treatment methods, with an average n=45. Dexamethasone group was treated with dexamethasone group, and itrepopopa group was treated with dexamethasone group and itrepopopa group combined with dexamethasone group, all n=45. The immune function, therapeutic effect and adverse reactions were compared. Results At 4 weeks after treatment, the levels of interleukin (IL)-2 and interferon (INF)-γ in the Altropopar group and dexamethasone group were lower than before treatment, and the levels of IL-4 in the Altropopar group and dexamethasone group were higher than before treatment. Aitripopal group was higher than dexamethasone group (P<0.05); At 4 weeks after treatment, the proportions of platelet (PLT)≥30×109/L were 68.89% and 40.00% in the Altropopar group and dexamethasone group, and the proportions of PLT≥50×109/L were 55.55% and 20.00%, respectively. The proportions in the Altropopar group were higher than those in the dexamethasone group (P<0.05). The proportions of PLT≥50×109/L in the half time and dexamethasone groups were 66.67% and 33.33%, respectively, and the proportions of PLT≥50×109/L for at least one time were 93.33% and 44.44%, respectively. The proportions of PLT≥50×109/L at least once after 9 months of treatment were 60.00% and 26.67%, respectively, and the attripopal group was higher than dexamethasone group (P<0.05). A comparison of the adverse reaction rate between aitopopal group and dexamethasone group (P>0.05). Conclusion Aitracopal can significantly reduce the risk of bleeding in patients with ITP, improve immune function, improve therapeutic effect, and high safety. |
| |
| Keywords: | |
|
| 点击此处可从《中国现代医生》浏览原始摘要信息 |
|
点击此处可从《中国现代医生》下载全文 |
|
